title: Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis.
abstract: Momelotinib (a JAK1 and JAK2 inhibitor) induces both anaemia and spleen responses in myelofibrosis (MF). Momelotinib treatment-emergent peripheral neuropathy (TE-PN) was documented in 44 (44%) of 100 MF patients treated at our institution; median time of TE-PN onset was 32 weeks and duration 11 months. Improvement after drug dose reduction or discontinuation was documented in only two patients. TE-PN was significantly associated with treatment response (P = 0·02) and longer survival (P = 0·048) but significance was lost during multivariate analysis that included treatment duration. TE-PN did not correlate with initial or maximum momelotinib dose or previous treatment with JAK inhibitor or thalidomide.
authors.affiliation: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
authors.forename: Ramy A
authors.initials: RA
authors.lastname: Abdelrahman
authors.forename: Kebede H
authors.initials: KH
authors.lastname: Begna
authors.forename: Aref
authors.initials: A
authors.lastname: Al-Kali
authors.forename: William J
authors.initials: WJ
authors.lastname: Hogan
authors.forename: Mark R
authors.initials: MR
authors.lastname: Litzow
authors.forename: Animesh
authors.initials: A
authors.lastname: Pardanani
authors.forename: Ayalew
authors.initials: A
authors.lastname: Tefferi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D053613:Janus Kinase 1 / Q000037:antagonists & inhibitors; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors; D008297:Male; D008875:Middle Aged; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000201:enzymology / Q000453:epidemiology*; D015995:Prevalence; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000201:enzymology / Q000453:epidemiology*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D012307:Risk Factors
chemical_list: D001549:Benzamides; D011743:Pyrimidines; C546012:N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide; C507904:JAK1 protein, human; C507924:JAK2 protein, human; D053613:Janus Kinase 1; D053614:Janus Kinase 2
keywords: momelotinib; myelofibrosis; myeloproliferative; neuropathy